The two companies were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Tag Archive for: Viatris
Mylan and several major drugmakers such as Israel’s Teva Pharmaceutical Industries and India’s Sun Pharmaceutical Industries have been under the DOJ’s scanner for more than eight years over alleged anticompetitive business practices in fixing prices of certain generic drugs.
Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
Bayer continued its leadership shuffle not only at its world headquarters in Germany but at two U.S.–based subsidiaries. Yet most of the executive movement of late has been at smaller companies.
Britain’s competition watchdog said Theramex’s purchase of European rights to two of Viatris’ women’s healthcare products ranges could lead to higher prices and fewer options for hormone replacement therapies (HRT).
The U.S. Court of Appeals for the Federal Circuit on Monday ruled in favor of Teva Pharmaceuticals and Viatris, finding that the final Johnson & Johnson patent over its schizophrenia drug Invega Sustenna is invalid.
The U.S. FDA has declined to approve Viatris and Mapi Pharma’s once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday.
The FDA will kick off March with three target action dates, including one for an insomnia treatment and another for a multiple sclerosis therapy.
Drugmaker Viatris said on Sunday it had reached agreements to divest some of its businesses for a total of up to $3.6 billion.
The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.